

Morocco

COUNTRY GENERAL INFORMATION

Total population:	35 126 274
Gender F/M (%):	50.4 / 49.6
Population, age group <15 / ≥ 15 years (%):	28 / 72
Life expectancy at birth (F/M, years):	77 / 75
GDP (PPP int \$):	7891
Income status:	Lower middle income
Number of 2 nd sub-national administrative level divisions, name:	75, Province



EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	92	3022	1880	N/A
Number of relapses: ¹	No data	11	1	N/A
Total number of cases:	92	3035^A	1885^B	N/A
Imported cases (#, %):	0, 0%	0, 0%	5, 0%	No data
Gender distribution (% F):	54	55	51	N/A
Age group distribution (% <5 / 5-14 / >14):	74 / 17 / 9	39 / 30 / 31	25 / 30 / 45	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.05	1.69	6.56	N/A
Number of endemic 2 nd sub-national administrative level divisions:	34	38	9	N/A
Population at risk (% # at risk / total population): ²	48% 17 015 716/ 35 126 274	51% 17 901 986/ 35 126 274	8% 2 873 339/ 35 126 274	N/A
Was there any outbreak?	No	No	Yes	N/A
Number of new foci: ³	2	1	1	N/A



Monthly distribution of new cases (January-December)

2016	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	13	3	7	9	18	15	9	2	7	4	2	3
ACL	222	341	342	328	422	189	112	116	202	196	218	347
ZCL	258	152	135	81	95	45	13	22	70	241	353	415

N/A not applicable; VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis



Number of new cases and Incidence rate/10 000 at the national level from 2001 to 2016



^AIncludes 2 cases classified as "unspecified"


^BIncludes 4 cases classified as "unspecified"

¹Relapse in this country is defined for VL as: "non response 3 weeks after start of treatment" and for CL as: "reappearance of lesion 6 weeks after start of treatment"

²Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

³Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever"

Disease distribution of new VL, ACL and ZCL cases at Province level per 10 000 population (2016)



CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1997
Type of surveillance (CL / VL):	Vertical / Vertical
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	No data
Year latest national guidelines (CL / VL):	2010 / 2010
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	Yes
Number of leishmaniasis health facilities (CL / VL):	No data / No data

DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	0	390 280	256 000	N/A
Number of people screened passively for:	No data	4381	6185	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	3% (3/92)	72% (2177/3024)	23% (431/1884)	N/A
Proportion of positive slides (% , # slides + / total slides):	100% (3/3)	50% (2177/4381)	7% (431/6185)	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	No data	28% (847/3024)	77% (1453/1884)	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Meglumine antimoniate

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	99% (91/92)	No data	No data
Initial cure rate (% , # cases initially cured / new cases):	99% (91/92)	100% (3022/3022)	100% (1880/1880)
Failure rate (% , # cases with treatment failure / new cases): ⁴	1% (1/92)	No data	0% (0/1880)
Case fatality rate (% , # cases who died / new cases):	3% (3/92)	No data	No data

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

⁴Failure in this country is defined for VL as: "Persistence of symptoms during the treatment period" and for CL as: "Bad evolution of lesion after 2 weeks of treatment or persistence of lesion after 6 weeks of treatment"